MXPA05009905A - Composicion farmaceutica y procedimiento para el tratamiento y prevencion de la hiperplasia prostatica y la prostatitis a partir de los frutos de roystones regia (palma real). - Google Patents
Composicion farmaceutica y procedimiento para el tratamiento y prevencion de la hiperplasia prostatica y la prostatitis a partir de los frutos de roystones regia (palma real).Info
- Publication number
- MXPA05009905A MXPA05009905A MXPA05009905A MXPA05009905A MXPA05009905A MX PA05009905 A MXPA05009905 A MX PA05009905A MX PA05009905 A MXPA05009905 A MX PA05009905A MX PA05009905 A MXPA05009905 A MX PA05009905A MX PA05009905 A MXPA05009905 A MX PA05009905A
- Authority
- MX
- Mexico
- Prior art keywords
- acid
- fatty acids
- extract
- pharmaceutical composition
- fruits
- Prior art date
Links
- 235000006595 Roystonea elata Nutrition 0.000 title claims abstract description 48
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 9
- 240000007186 Roystonea regia Species 0.000 title claims abstract 7
- 238000011282 treatment Methods 0.000 title claims description 22
- 230000002265 prevention Effects 0.000 title claims description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title abstract description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title abstract description 6
- 241000899648 Roystonea Species 0.000 title abstract description 5
- 235000008947 Roystonea oleracea Nutrition 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 201000004384 Alopecia Diseases 0.000 claims abstract description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 14
- 238000000605 extraction Methods 0.000 claims abstract description 9
- 231100000360 alopecia Toxicity 0.000 claims abstract description 8
- 230000007062 hydrolysis Effects 0.000 claims abstract description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 8
- 206010020112 Hirsutism Diseases 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 235000021588 free fatty acids Nutrition 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 3
- 239000003960 organic solvent Substances 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 49
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 150000004665 fatty acids Chemical class 0.000 claims description 15
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 14
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 13
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 12
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 7
- 239000005642 Oleic acid Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 6
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000005639 Lauric acid Substances 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 235000021360 Myristic acid Nutrition 0.000 claims description 6
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- 235000021314 Palmitic acid Nutrition 0.000 claims description 6
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 229960002446 octanoic acid Drugs 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 150000002430 hydrocarbons Chemical class 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000007127 saponification reaction Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 239000002453 shampoo Substances 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 abstract description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 48
- 244000208347 Roystonea elata Species 0.000 description 37
- 210000002307 prostate Anatomy 0.000 description 25
- 229960003604 testosterone Drugs 0.000 description 24
- 240000006661 Serenoa repens Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 235000005318 Serenoa repens Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 229960003473 androstanolone Drugs 0.000 description 9
- 239000010018 saw palmetto extract Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000000585 Mann–Whitney U test Methods 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 239000008158 vegetable oil Substances 0.000 description 6
- 239000003098 androgen Substances 0.000 description 5
- 230000003676 hair loss Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000013222 sprague-dawley male rat Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000021022 fresh fruits Nutrition 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 244000274883 Urtica dioica Species 0.000 description 2
- 235000009108 Urtica dioica Nutrition 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002160 alpha blocker Substances 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- 239000005418 vegetable material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000011795 OF1 mouse Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- -1 sopentane Chemical compound 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030062A CU23256A1 (es) | 2003-03-20 | 2003-03-20 | EXTRACTO OBTENIDO A PARTIR DE FRUTOS DE ROYSTONEA REGIA UTILIZADO CONTRA LA HIPERPLASIA PROSTáTICA Y LA PROSTATITIS |
| PCT/CU2004/000004 WO2004082696A1 (es) | 2003-03-20 | 2004-03-15 | Composición farmacéutica y procedimiento para el tratamiento y prevención de la hiperplasia prostática y la prostatitis a partir de los frutos de roystones regia (palma real) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05009905A true MXPA05009905A (es) | 2006-03-21 |
Family
ID=40210497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05009905A MXPA05009905A (es) | 2003-03-20 | 2004-03-15 | Composicion farmaceutica y procedimiento para el tratamiento y prevencion de la hiperplasia prostatica y la prostatitis a partir de los frutos de roystones regia (palma real). |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20060228429A1 (enExample) |
| EP (1) | EP1623740B1 (enExample) |
| JP (1) | JP4693766B2 (enExample) |
| KR (1) | KR100758256B1 (enExample) |
| CN (1) | CN100366246C (enExample) |
| AT (1) | ATE394139T1 (enExample) |
| AU (1) | AU2004222693B2 (enExample) |
| BR (1) | BRPI0409056A (enExample) |
| CA (1) | CA2519410C (enExample) |
| CR (1) | CR8001A (enExample) |
| CU (1) | CU23256A1 (enExample) |
| DE (1) | DE602004013572D1 (enExample) |
| DK (1) | DK1623740T3 (enExample) |
| EC (1) | ECSP056028A (enExample) |
| ES (1) | ES2306999T3 (enExample) |
| IL (1) | IL170997A (enExample) |
| MX (1) | MXPA05009905A (enExample) |
| NO (1) | NO333290B1 (enExample) |
| NZ (1) | NZ542361A (enExample) |
| PT (1) | PT1623740E (enExample) |
| RU (1) | RU2331434C2 (enExample) |
| UA (1) | UA82224C2 (enExample) |
| WO (1) | WO2004082696A1 (enExample) |
| ZA (1) | ZA200507575B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4926395B2 (ja) * | 2004-11-30 | 2012-05-09 | 学校法人 名城大学 | 抗ｍｒｓａ用組成物 |
| KR100769412B1 (ko) * | 2006-09-13 | 2007-10-22 | 주식회사 벤스랩 | Ｐｒ-119 복합생약 추출물을 함유하는 전립선 비대증의예방 및 치료용조성물 |
| WO2010118362A1 (en) | 2009-04-09 | 2010-10-14 | The Regents Of The University Of Colorado, A Body Corporate | Methods and compositions for inducing physiological hypertrophy |
| CU24143B1 (es) * | 2012-06-19 | 2016-01-29 | Cnic Ct Nac Investigaciones | Ingrediente activo para el tratamiento y la prevención de la inflamación y el estrés oxidativo, así como su procedimiento de obtención a partir de los frutos de acrocomina crispa y/o acrocomia aculeata |
| CA2957363C (en) * | 2014-08-12 | 2022-06-21 | Institut de Recherche en Semiochimie et Ethologie Appliquee | Palmitoleic acid for use in inhibiting the attachment of sea lice to fish |
| KR102273967B1 (ko) * | 2014-10-31 | 2021-07-08 | (주)아모레퍼시픽 | 인삼씨유를 함유하여 전립선 비대증을 예방 및 치료하는 조성물 |
| JP2017214342A (ja) * | 2016-06-02 | 2017-12-07 | 日清オイリオグループ株式会社 | 排尿障害の予防用又は改善用組成物 |
| JP6628946B2 (ja) | 2017-12-26 | 2020-01-15 | 大太朗 福岡 | 増毛、頭皮若しくは皮膚の改質、創傷治癒、骨形成促進、または毛髪の改質に用いるための医薬組成物 |
| AU2019212513B2 (en) | 2018-01-26 | 2024-10-31 | Fluidx Medical Technology, Llc | Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion |
| EP4082518A1 (en) | 2021-04-28 | 2022-11-02 | Cnce Innovacion, S.L. | Fatty acid compositions for the treatment and prevention of hair loss and alopecia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU21519A1 (en) * | 1983-03-23 | 1987-06-09 | Inst De Quimica Y Biolog Ex | Procedure to facilitate the grinding of roystonea regia fruits |
| TW408127B (en) * | 1993-09-17 | 2000-10-11 | Glaxo Inc | Androstenones |
| CN1184670A (zh) * | 1997-12-23 | 1998-06-17 | 张冰 | 一种治疗前列腺增生、前列腺炎的药物组合物 |
| RU2140265C1 (ru) * | 1998-10-27 | 1999-10-27 | Чернобаев Николай Евгеньевич | Средство для лечения и профилактики доброкачественной гиперплазии простаты (дгп), простатита, импотенции, бесплодия и рака предстательной железы |
-
2003
- 2003-03-20 CU CU20030062A patent/CU23256A1/es unknown
-
2004
- 2004-03-15 PT PT04720576T patent/PT1623740E/pt unknown
- 2004-03-15 CN CNB2004800071887A patent/CN100366246C/zh not_active Expired - Lifetime
- 2004-03-15 RU RU2005130746/15A patent/RU2331434C2/ru not_active Application Discontinuation
- 2004-03-15 AU AU2004222693A patent/AU2004222693B2/en not_active Expired
- 2004-03-15 KR KR1020057017600A patent/KR100758256B1/ko not_active Expired - Lifetime
- 2004-03-15 JP JP2006504216A patent/JP4693766B2/ja not_active Expired - Fee Related
- 2004-03-15 UA UAA200508900A patent/UA82224C2/uk unknown
- 2004-03-15 MX MXPA05009905A patent/MXPA05009905A/es active IP Right Grant
- 2004-03-15 DK DK04720576T patent/DK1623740T3/da active
- 2004-03-15 NZ NZ542361A patent/NZ542361A/xx not_active IP Right Cessation
- 2004-03-15 BR BRPI0409056-0A patent/BRPI0409056A/pt not_active IP Right Cessation
- 2004-03-15 CA CA2519410A patent/CA2519410C/en not_active Expired - Fee Related
- 2004-03-15 ES ES04720576T patent/ES2306999T3/es not_active Expired - Lifetime
- 2004-03-15 EP EP04720576A patent/EP1623740B1/en not_active Expired - Lifetime
- 2004-03-15 AT AT04720576T patent/ATE394139T1/de active
- 2004-03-15 US US10/549,740 patent/US20060228429A1/en not_active Abandoned
- 2004-03-15 DE DE602004013572T patent/DE602004013572D1/de not_active Expired - Lifetime
- 2004-03-15 WO PCT/CU2004/000004 patent/WO2004082696A1/es not_active Ceased
-
2005
- 2005-09-19 ZA ZA200507575A patent/ZA200507575B/xx unknown
- 2005-09-20 EC EC2005006028A patent/ECSP056028A/es unknown
- 2005-09-20 IL IL170997A patent/IL170997A/en not_active IP Right Cessation
- 2005-09-20 CR CR8001A patent/CR8001A/es unknown
- 2005-10-20 NO NO20054847A patent/NO333290B1/no not_active IP Right Cessation
-
2009
- 2009-10-08 US US12/575,584 patent/US20100022649A1/en not_active Abandoned
- 2009-10-08 US US12/575,575 patent/US20100021574A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100021574A1 (en) | Pharmaceutical Composition and Procedure to Treat and Prevent Prostatic Hyperplasia and Prostatitis from the Royal Palm (Roystonea regia) Fruits | |
| Kalu et al. | Effect of kolaviron, a biflavanoid complex from Garcinia kola on some biochemical parameters in experimentally induced benign prostatic hyperplasic rats | |
| Talpur et al. | Comparison of Saw Palmetto (extract and whole berry) and Cernitin on prostate growth in rats | |
| CN105979956A (zh) | 用于抑制5-α还原酶的基于植物提取物的组合物 | |
| CN111265503B (zh) | 一种抑制5α-还原酶活性的组合物及其应用 | |
| RU2470657C2 (ru) | ПРИМЕНЕНИЕ ЭКСТРАКТОВ ИЛИ ЭКСТРАКТИВНЫХ ВЕЩЕСТВ ИЗ Piper cubeba L. В КАЧЕСТВЕ АКТИВНЫХ ИНГРЕДИЕНТОВ В ЛЕКАРСТВЕННОМ СРЕДСТВЕ ДЛЯ ЛЕЧЕНИЯ РАКОВЫХ ЗАБОЛЕВАНИЙ | |
| Winner et al. | Effect of fractions of kolaviron on some indices of benign prostatic hyperplasia in rats: identification of the constituents of the bioactive fraction using GC-MS | |
| JPH05194250A (ja) | サバルセルラタのリピド抽出物の酸分画から導かれた新規薬学的組成物及びその組成物を製造する方法 | |
| Uroko et al. | Combined ethanol extract of Hypselodelphys poggeana and Spermacoce radiata leaves ameliorate benign prostatic hyperplasia in rats via modulation of serum sex hormonal levels | |
| JP2006520331A5 (enExample) | ||
| Maccagnano et al. | A critical analysis of Permixon™ in the treatment of lower urinary tract symptoms due to benign prostatic enlargement | |
| HK1084059B (en) | Pharmaceutical composition and method for the treatment and prevention of prostatic hyperplasia and prostatitis using roystonea regia (royal palm) fruits | |
| AU2012223307A1 (en) | Methods of processing extracts of a T. wilfordii Hook F. plant | |
| Sarwar et al. | Piper longum hexane fraction induces infertility by modulation of inflammatory mediators and gonadotripin insufficiency in female rats | |
| CN108938710A (zh) | 烟豆或其提取物在制备治疗和/或预防关节炎的药物中的用途 | |
| JP7305546B2 (ja) | 前立腺の病変におけるＣｏｐａｉｆｅｒａ属オレオレジンの使用 | |
| Essiet et al. | Effect of Ethanol Root Bark Extract of Salacia lehmbachii Loes on Male Reproductive Hormones in Albino Rats | |
| Esiaba et al. | Annona muricata L. Fruit Pulp Improves Hormone Profile and Semen Quality in Testosterone-Induced Benign Prostatic Hyperplasia Male Rats. | |
| Gautam et al. | Hair Growth Activity of Seeds and Fruit Pulp of Eugenia jambolana (Jamun) | |
| Rajput et al. | GC PROFILING OF URTICA DIOICA FOR THE EFFICACY OF TRADITIONAL URTICATION THERAPY | |
| JP2020200325A (ja) | 牛蒡抽出物の使用 | |
| Arruzazabala et al. | Different ripening stages of Roystonea regia fruits influence their effects on testosterone-induced prostate enlargement in rats | |
| HK40017918A (en) | Use of copaifera oleoresin in pathologies of the prostate | |
| CA2876907A1 (en) | Compounds from the fruits of acrocomia crispa and acrocomia aculata against inflammation and oxidative stress | |
| FR2877577A1 (fr) | Extraits de fruits d'astrocaryum aculeatum a visee anti hypertrophie benigne de la prostate, anti inflammatoire et anti oxydante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |